Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastoma

Trial Profile

A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastoma

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Anaplastic large cell lymphoma; Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2018 Status changed from recruiting to suspended.
    • 18 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 21 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top